Castilia Life Sciences LLP has notified stock exchanges regarding the vesting of shares in Hikal Limited. This transfer follows the corporate restructuring where Castilia Life Sciences Private Limited (“Castilia Co”) converted into a Limited Liability Partnership (“Castilia LLP”). The Ministry of Corporate Affairs approved this conversion on February 17, 2026. Crucially, the aggregate shareholding of the Promoter Group in Hikal remains unchanged post-transaction.
Corporate Restructuring Notification
This disclosure serves to inform the Stock Exchanges regarding the change in the legal entity holding shares of Hikal Limited (BSE: 524735; NSE: HIKAL). The shares previously held by Castilia Life Sciences Private Limited have formally vested in the newly constituted entity, Castilia Life Sciences LLP.
This vesting occurred pursuant to the official conversion of the Private Limited Company (“Castilia Co”) into a Limited Liability Partnership (“Castilia LLP”). The Ministry of Corporate Affairs issued the Certificate of Registration for this conversion on February 17th, 2026. Consequently, all assets, rights, liabilities, and the shareholding interest in Hikal Limited transferred to Castilia LLP.
Shareholding Status Pre and Post-Transaction
The announcement confirms that this internal structural change has resulted in no change to the aggregate shareholding percentage held by the Promoters and the Promoter Group in the Target Company, Hikal Limited.
Detailed Shareholding Breakdown
The pre-transaction figures show the seller, Castilia Life Sciences Private Limited, holding 3,02,31,914 shares, representing 24.52% of the total share capital. Post-transaction, the acquirer, Castilia Life Sciences LLP, now holds these 3,02,31,914 shares, equating to 24.52% of the total share capital. The transferor entity holds NIL shares post-conversion.
For Castilia Life Sciences LLP, the filing was signed by Sugandha Hiremath, Designated Partner, on 18th February 2026 in Mumbai.
Source: BSE
